Program and patient characteristics for the United States Expanded Access Program to COVID-19 convalescent plasma

BACKGROUND: The United States (US) Expanded Access Program (EAP) to COVID-19 convalescent plasma was initiated in response to the rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease-2019 (COVID-19). While randomized clinical trials...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:medRxiv
Päätekijät: Senefeld, Jonathon W., Johnson, Patrick W., Kunze, Katie L., van Helmond, Noud, Klassen, Stephen A., Wiggins, Chad C., Bruno, Katelyn A., Golafshar, Michael A., Petersen, Molly M., Buras, Matthew R., Klompas, Allan M., Sexton, Matthew A., Soto, Juan C. Diaz, Baker, Sarah E., Shepherd, John R.A., Verdun, Nicole C., Marks, Peter, van Buskirk, Camille M., Winters, Jeffrey L., Stubbs, James R., Rea, Robert F., Herasevich, Vitaly, Whelan, Emily R., Clayburn, Andrew J., Larson, Kathryn F., Ripoll, Juan G., Andersen, Kylie J., Vogt, Matthew N.P., Dennis, Joshua J., Regimbal, Riley J., Bauer, Philippe R., Blair, Janis E., Wright, Katherine, Greenshields, Joel T., Paneth, Nigel S., Fairweather, DeLisa, Wright, R. Scott, Casadevall, Arturo, Carter, Rickey E., Joyner, Michael J.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Cold Spring Harbor Laboratory 2021
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC8043472/
https://ncbi.nlm.nih.gov/pubmed/33851175
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1101/2021.04.08.21255115
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia